Why Target Immune Cells for Plasma Treatment of Cancer

Miller, Vandana; Lin, Abraham; Fridman, Alexander

doi:10.1007/s11090-015-9676-z

Cited by 108 publications

(83 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…leading to activation of macrophages, generation of tumorspecific antigens and associated cytokine release [93]. If plasma therapies are developed that can controllably modulate immune responses with minimal side effects, the potential for developing important new plasma-based therapies will be greatly advanced.…”

Section: Medical Applicationsmentioning

confidence: 99%

The 2017 Plasma Roadmap: Low temperature plasma science and technology

Adamovich

Baalrud

Bogaerts

et al. 2017

J. Phys. D: Appl. Phys.

791

549

View full text Add to dashboard Cite

Section: Medical Applicationsmentioning

confidence: 99%

The 2017 Plasma Roadmap: Low temperature plasma science and technology

Adamovich

Baalrud

Bogaerts

et al. 2017

J. Phys. D: Appl. Phys.

791

549

View full text Add to dashboard Cite

“…Several recent studies have suggested that non-thermal plasma treatment induces ICD and stimulates macrophages [25,[33][34][35]. Non-thermal plasma treatment was shown to stimulate extracellular ATP secretion and enhance cell death via ICD-mediated macrophage stimulation.…”

Section: Indirect Treatment: Plasma-assisted Cancer Immunotherapymentioning

confidence: 99%

New Hopes for Plasma-Based Cancer Treatment

Tanaka

Mizuno

Ishikawa

et al. 2018

Plasma

View full text Add to dashboard Cite

show abstract

“…The observed beneficial effects in wound healing [4][5][6] and cancer [7][8][9] have significantly spurred research efforts and novel findings in recent years. Promising in vitro research investigations are an ethical and scientific necessity for translation of plasma applications to in vivo models and eventually to humans.…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Floating-Electrode DBD and kINPen Jet: Plasma Parameters to Achieve Similar Growth Reduction in Colon Cancer Cells Under Standardized Conditions

Bekeschus

Lin

Fridman

et al. 2017

Plasma Chem Plasma Process

Self Cite

View full text Add to dashboard Cite

A comparative study of two plasma sources (floating-electrode dielectric barrier discharge, DBD, Drexel University; atmospheric pressure argon plasma jet, kINPen, INP Greifswald) on cancer cell toxicity was performed. Cell culture protocols, cytotoxicity assays, and procedures for assessment of hydrogen peroxide (H 2 O 2 ) were standardized between both labs. The inhibitory concentration 50 (IC50) and its corresponding H 2 O 2 deposition was determined for both devices. For the DBD, IC50 and H 2 O 2 generation were largely dependent on the total energy input but not pulsing frequency, treatment time, or total number of cells. DBD cytotoxicity could not be replicated by addition of H 2 O 2 alone and was inhibited by larger amounts of liquid present during the treatment. Jet plasma toxicity depended on peroxide generation as well as total cell number and amount of liquid. Thus, the amount of liquid present during plasma treatment in vitro is key in attenuating short-lived species or other physical effects from plasmas. These in vitro results suggest a role of liquids in or on tissues during plasma treatment in a clinical setting. Additionally, we provide a platform for correlation between different plasma sources for a predefined cellular response.

show abstract

Why Target Immune Cells for Plasma Treatment of Cancer

Cited by 108 publications

References 64 publications

The 2017 Plasma Roadmap: Low temperature plasma science and technology

The 2017 Plasma Roadmap: Low temperature plasma science and technology

New Hopes for Plasma-Based Cancer Treatment

A Comparison of Floating-Electrode DBD and kINPen Jet: Plasma Parameters to Achieve Similar Growth Reduction in Colon Cancer Cells Under Standardized Conditions

Contact Info

Product

Resources

About